Summary
Updated Aug 30, 2026
Ruxandra Draghia-Akli is EVP, Research & Development of NOVAVAX INC (NVAX). 4 SEC Form 4 filings on record going back to 2024, most recently on 9 March 2026.
Recent Transactions
4Every recent SEC Form 4 transaction Ruxandra Draghia-Akli has reported, most recent first.
Other Insiders Active in the Same Sector
No other insider has filed at Ruxandra Draghia-Akli's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Amirali Talasaz - $73.75M of GH open-market activity in the last 12 months
- James E. Flynn - $70.87M of NUVL open-market activity in the last 12 months
- Joaquin Duato - $66.84M of JNJ open-market activity in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $63.45M of SEPN open-market activity in the last 12 months
- BVF PARTNERS L P - $62.96M of MLTX open-market activity in the last 12 months
- BROADWOOD PARTNERS, L.P. - $62.75M of STAA open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Ruxandra Draghia-Akli?
Ruxandra Draghia-Akli is a corporate insider, tracked as EVP, Research & Development of NOVAVAX INC (NVAX). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Ruxandra Draghia-Akli last file a Form 4?
The most recent primary Form 4 on record is dated 9 March 2026, one of 4 filings going back to 2024.
Where can I see all of Ruxandra Draghia-Akli's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Ruxandra Draghia-Akli and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
